◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Cosmo Bio Company,Limited (3386) Financial History

Name: Cosmo Bio Company,Limited (3386) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Diagnostics & Research · DATA UPDATED 2026-08-10

Cosmo Bio Company,Limited (3386) operates in the Diagnostics & Research industry and is headquartered in Koto, Japan with about 182 employees. Its market capitalization is roughly JPY 7 billion. In the fiscal year ended 2025-12-31, 3386 reported JPY 10.8B in revenue and JPY 337M in net income.

Cosmo Bio Company,Limited, together with its subsidiaries, operates as a life science trading company worldwide. It is involved in the import, export, manufacture, marketing, sales, and customer support of life science research bio tools, such as reagents, kits, instruments, and software.

Interactive charts & full statements →

3386 Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Revenue	JPY 10.8B	JPY 10.0B	JPY 9.3B	JPY 9.6B	—
Gross Profit	JPY 3.7B	JPY 3.3B	JPY 3.2B	JPY 3.4B	—
Operating Income (EBIT)	JPY 343M	JPY 319M	JPY 520M	JPY 816M	—
Net Income	JPY 337M	JPY 262M	JPY 442M	JPY 517M	—

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

3386 Free Cash Flow History

Cash flow	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Dividends Paid	(JPY 348M)	(JPY 175M)	(JPY 197M)	(JPY 232M)	—

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

3386 Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	JPY 12.7B	JPY 11.7B	JPY 10.9B	JPY 10.3B	—
Total Liabilities	JPY 2.7B	JPY 2.2B	JPY 1.8B	JPY 1.7B	—

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 3386 viewer.

Other Companies in Diagnostics & Research

4671 · FALCO HOLDINGS Co., Ltd. — $27 billion
6127 · Joinn Laboratories(China)Co.,Ltd. — $21 billion
ERF · Eurofins Scientific SE — $12 billion
BIM · bioMérieux S.A. — $9 billion
BLLN · BillionToOne, Inc. — $4 billion
ADPT · Adaptive Biotechnologies Corporation — $4 billion
VCYT · Veracyte, Inc. — $4 billion
GRAL · GRAIL, Inc. — $3 billion

← 3383 All “0-9” companies 3387 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.